Coated stent comprising an HMG-CoA reductase inhibitor
Stents with coatings comprising a combination of a restenosis inhibitor comprising an HMG-CoA reductase inhibitor and a carrier. Also provided are methods of coating stents with a combination of an HMG-CoA reductase inhibitor and a carrier. A preferred example of a restenosis inhibitor is cerivastatin. The stent coatings have been shown to release restenosis inhibitors in their active forms.
1. A coated stent comprising:
a stent; and
a coating on the stent, the coating comprising:
an HMG-CoA reductase inhibitor in an amount between about 1 wt. % and about 50 wt. %, based on a total weight of the coating; and
a carrier for the HMG-CoA reductase inhibitor,
wherein coating is configured to release the HMG-CoA reductase from the stent at a rate of >20 μg/ml per day.
2. The coated stent of claim 1 , wherein the coating comprises the HMG-CoA reductase inhibitor in an amount between about 5 wt. % and about 30 wt. %, based on a total weight of the coating.
3. The coated stent of claim 1 , wherein the coating comprises the HMG-CoA reductase inhibitor in an amount between about 2 wt. % and about 20 wt. %, based on a total weight of the coating.
4. The coated stent of claim 1 , wherein the HMG-CoA reductase inhibitor is selected from a group consisting of: cerivastatin, atorvastatin, simvastatin, fluvastatin, lovastatin, and pravastatin.
5. The coated stent of claim 1 , wherein the HMG-CoA reductase inhibitor is cerivastatin.
6. The coated stent of claim 1 , wherein the coating further comprises a restenosis inhibitor which is not an HMG-CoA reductase inhibitor.
7. The coated stent of claim 1 , wherein the carrier is non-reactive with the HMG-CoA reductase inhibitor.
8. The coated stent of claim 1 , wherein the carrier comprises a polymeric carrier that is physically bound to the HMG-CoA reductase inhibitor.
9. The coated stent of claim 1 , wherein the carrier comprises a polymeric carrier that is chemically bound to the HMG-CoA reductase inhibitor.
10. The coated stent of claim 1 , wherein the carrier comprises a polymeric biodegradable carrier.
11. The coated stent of claim 1 , wherein the carrier comprises a nonpolymeric carrier.
12. The coated stent of claim 11 , wherein the nonpolymeric carrier is selected from a group consisting of: Vitamin E, Vitamin E acetate, Vitamin E succinate, oleic acid, peanut oil and cottonseed oil.
13. The coated stent of claim 1 , wherein the carrier is liquid at body temperature.
14. The coated stent of claim 1 , wherein the carrier is solid at body temperature.
15. The coated stent of claim 1 , wherein the coating further comprises one or more bioactive compounds selected from a group consisting of: paclitaxel, paclitaxel analogs, actinomycin D, actinomycin D analogs, rapamycin, rapamycin analogs, and mixtures thereof.
16. A coated stent comprising:
a stent; and
a coating comprising:
an HMG-CoA reductase inhibitor in an amount between about 1 wt. % and about 50 wt. %, based on a total weight of the coating; and
a polymeric biodegradable carrier for the HMG-CoA reductase inhibitor, the polymeric biodegradable carrier comprising a polymer selected from polycaprolactone, ethylene-vinyl acetate polymer, and a two-part silicone rubber,
wherein the coating is configured to release the HMG-CoA reductase Inhibitor from the stent at a rate of >20 μg/ml per day.
17. The coated stent of claim 16 , wherein the coating comprises the HMG-CoA reductase inhibitor in an amount between about 5 wt. % and about 30 wt. %, based on a total weight of the coating composition.
18. The coated stent of claim 16 , wherein the coating comprises the HMG-CoA reductase inhibitor in an amount between about 2 wt. % and about 20 wt. %, based on a total weight of the coating composition.
19. The coated stent of claim 16 , wherein the HMG-CoA reductase inhibitor is selected from a group consisting of: cerivastatin, atorvastatin, simvastatin, fluvastatin, lovastatin, and pravastatin.
20. The coated stent of claim 16 , wherein the coating further comprises a restenosis inhibitor which is not an HMG-CoA reductase inhibitor.
21. The coated stent of claim 16 , wherein the coating further comprises one or more bioactive compounds selected from a group consisting of: paclitaxel, paclitaxel analogs, actinomycin D, actinomycin D analogs, rapamycin, rapamycin analogs, and mixtures thereof.